Assessment of miR-182, miR-221 and CEA expression in the peripheral blood of oral squamous cell carcinoma (OSCC) patients
,
Abstract
Introduction: Head and neck cancer is the sixth common cancer in the world, of which the oral cavity is the most frequent type. It was diagnosed on more than 377,700 cases worldwide in 2020. Access to high-quality care leading to a more specific and earlier diagnosis of this cancer is crucial. Therefore, researchers attempt to investigate and detect efficient biological tumor marker. The present study aimed to investigate the changes in the expressions of miR-182, miR-221, and carcinoembryonic antigen (CEA) in the peripheral blood of patients with oral squamous cell carcinoma (OSCC) and compare them with healthy individuals to detect early OSCC. Materials and Methods: 30 peripheral blood samples from patients with OSCC (19 male and 11 female), aged 25-70, were obtained from the cancer institute of Tehran University of Medical Sciences, and 30 peripheral blood samples from healthy individuals (20 male and 10 female) aged 26-70 were collected. Real-time PCR was carried out to investigate the differences in the expressions of miR-182, miR-221, and ELISA was used to measure CEA protein expression. Results: Among the subjects with OSCC 83% showed miR-182 expression, 93% revealed miR-221 expression and 96% demonstrated CEA expression. Whereas, these expressions were 26%, 20% and 13%, respectively, for the healthy group. The simultaneous detection of miR-182 and miR-221 was 73% in the individuals with OSCC. The simultaneous observation of miR-182, miR-221, and CEA in the group with OSCC was 60%. The expression level of miR-221 in the group with OSCC was 2.63 times that of the healthy subjects, and the expression level of miR-182 in the individuals with OSCC was 2.29 times that of the healthy group. Conclusion: The results of this study nominated miR-182, miR-221, and CEA as biomarkers for early diagnosis and consequently improvement of survival rate of patients suffering from OSCC. Keywords: OSCC; MiR-182; MiR-221; CEA; Biomarker.
1. World Health Organization, International Agency for Research on Cancer, & World Health Organization. (2020). Global cancer observatory.
2. Petersen, P. E. (2003). The World Oral Health Report 2003: continuous improvement of oral health in the 21st century–the approach of the WHO Global Oral Health Programme. Community Dentistry and oral epidemiology, 31, 3-24.
3. Chester, D., Ephros, H., Haghighi, K., Kupiec-Sce, B., Lederman, D., Meddis, M., ... & Smith, S. L. (2008). Oral and Oropharyngeal Cancer. NJ, USA, Department of Health.
4. Woolgar, J. A. (2005). Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. oraloncology. 2005Oral Oncol. 2006 Mar; 42 (3): 229-39.
5. Aghiorghiesei, O., Zanoaga, O., Nutu, A., Braicu, C., Campian, R. S., Lucaciu, O., & Berindan Neagoe, I. (2022). The world of Oral cancer and its risk factors viewed from the aspect of MicroRNA expression patterns. Genes, 13(4), 594.
6. Rezapour, A., Jahangiri, R., Olyaeemanesh, A., Kalaghchi, B., Nouhi, M., & Nahvijou, A. (2018). The economic burden of oral cancer in Iran. PloS one, 13(9), e0203059.
7. Massano, J., Regateiro, F. S., Januário, G., & Ferreira, A. (2006). Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontology, 102(1), 67-76.
8. Cervino, G., Fiorillo, L., Herford, A. S., Romeo, U., Bianchi, A., Crimi, S., ... & Cicciù, M. (2019). Molecular biomarkers related to oral carcinoma: clinical trial outcome evaluation in a literature review. Disease markers, 2019.
9. Santosh, A. B. R., Jones, T., & Harvey, J. (2016). A review on oral cancer biomarkers: Understanding the past and learning from the present. Journal of cancer research and therapeutics, 12(2), 486-492.
10. Friedman, R. C., Farh, K. K. H., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome research, 19(1), 92-105.
11. Nagadia, R., Pandit, P., Coman, W. B., Cooper-White, J., & Punyadeera, C. (2013). miRNAs in head and neck cancer revisited. Cellular Oncology, 36, 1-7.
12. Troiano, G., Boldrup, L., Ardito, F., Gu, X., Muzio, L. L., & Nylander, K. (2016). Circulating miRNAs from blood, plasma or serum as promising clinical biomarkers in oral squamous cell carcinoma: A systematic review of current findings. Oral Oncology, 63, 30-37.
13. Arya, D., Sachithanandan, S. P., Ross, C., Palakodeti, D., Li, S., & Krishna, S. (2018). MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia. Cell death & disease, 8(1), e2547-e2547.
14. Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., ... & Garraway, L. A. (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer research, 68(3), 664-673.
15. Bandrés, E., Cubedo, E., Agirre, X., Malumbres, R., Zarate, R., Ramirez, N., ... & Garcia-Foncillas, J. (2006). Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Molecular cancer, 5(1), 1-10.
16. Agirre, X., Jiménez-Velasco, A., San José-Enériz, E., Garate, L., Bandrés, E., Cordeu, L., ... & Prosper, F. (2008). Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Molecular cancer research, 6(12), 1830-1840.
17. Navarro, A., Gaya, A., Martinez, A., Urbano-Ispizua, A., Pons, A., Balagué, O., ... & Monzo, M. (2008). MicroRNA expression profiling in classic Hodgkin lymphoma. Blood, The Journal of the American Society of Hematology, 111(5), 2825-2832.
18. Di Martino, M. T., Rossi, M., Caracciolo, D., Gullà, A., Tagliaferri, P., & Tassone, P. (2016). Mir-221/222 are promising targets for innovative anticancer therapy. Expert Opinion on Therapeutic Targets, 20(9), 1099-1108.
19. Xie, D., Yuan, P., Wang, D., Jin, H., & Chen, H. (2017). Expression and prognostic significance of miR-375 and miR-221 in liver cancer. Oncology Letters, 14(2), 2305-2309.
20. Hussein, S., Mosaad, H., Rashed, H. E., & El-Anwar, M. W. (2017). Up-regulated miR-221 expression as a molecular diagnostic marker in laryngeal squamous cell carcinoma and its correlation with Apaf-1 expression. Cancer Biomarkers, 19(3), 279-287.
21. Zhang, Y., Zhao, Y., Sun, S., Liu, Z., Zhang, Y., & Jiao, S. (2016). Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients. Tumor Biology, 37, 10155-10160.
22. Wu, Q., Ren, X., Zhang, Y., Fu, X., Li, Y., Peng, Y., ... & Yin, G. (2018). MiR-221-3p targets ARF4 and inhibits the proliferation and migration of epithelial ovarian cancer cells. Biochemical and biophysical research communications, 497(4), 1162-1170.
23. Vergho, D. C., Kneitz, S., Kalogirou, C., Burger, M., Krebs, M., Rosenwald, A., ... & Kneitz, B. (2014). Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava. PloS one, 9(10), e109877.
24. Hall, C., Clarke, L., Pal, A., Buchwald, P., Eglinton, T., Wakeman, C., & Frizelle, F. (2019). A review of the role of carcinoembryonic antigen in clinical practice. Annals of coloproctology, 35(6), 294.
25. Grunnet, M., & Sorensen, J. B. (2012). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung cancer, 76(2), 138-143.
26. Sørensen, C. G., Karlsson, W. K., Pommergaard, H. C., Burcharth, J., & Rosenberg, J. (2016). The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence–A systematic review. International Journal of Surgery, 25, 134-144.
27. Najafi, S., Khayamzadeh, M., Jafari Ghavamabad, A., Moradi, F., & Bafrouii, S. D. (2018). A 5 year Epidemiological Study on Oral and Pharyngeal Cancers from Cancer Registration Centers in Tehran. Journal of Iranian Medical Council, 1(2), 63-68.
28. Döbróssy, L. (2005). Epidemiology of head and neck cancer: magnitude of the problem. Cancer and Metastasis Reviews, 24, 9-17.
29. Silveira, A., Gonçalves, J., Sequeira, T., Ribeiro, C., Lopes, C., Monteiro, E., & Pimentel, F. L. (2012). Head and neck cancer: health related quality of life assessment considering clinical and epidemiological perspectives. Revista Brasileira de epidemiología, 15, 38-48.
30. Harding, S., Sanipour, F., & Moss, T. (2014). Existence of benefit finding and posttraumatic growth in people treated for head and neck cancer: a systematic review. PeerJ, 2, e256.
31. Yang, W., Zhao, S., Liu, F., & Sun, M. (2014). Health-related quality of life after mandibular resection for oral cancer: reconstruction with free fibula flap. Medicina oral, patologia oral y cirugia bucal, 19(4), e414.
32. Baykul, T., Yilmaz, H. H., Aydin, Ü., Aydin, M. A., Aksoy, M. C., & Yildirim, D. (2010). Early diagnosis of oral cancer. Journal of International Medical Research, 38(3), 737-749.
33. Scott, S. E., Grunfeld, E. A., & McGurk, M. (2006). Patient's delay in oral cancer: a systematic review. Community dentistry and oral epidemiology, 34(5), 337-343.
34. Dikova, V., Jantus-Lewintre, E., & Bagan, J. (2021). Potential non-invasive biomarkers for early diagnosis of oral squamous cell carcinoma. Journal of Clinical Medicine, 10(8), 1658.
35. Liang, K. H., Lin, Y. Y., Chiang, S. H., Tsai, E. T., Lo, W. L., Wang, C. L., ... & Hung, K. F. (2021). Recent progress of biomarkers in oral cancers. Journal of the Chinese Medical Association, 84(11), 987-992.
36. Arantes, L. M. R. B., De Carvalho, A. C., Melendez, M. E., & Lopes Carvalho, A. (2018). Serum, plasma and saliva biomarkers for head and neck cancer. Expert review of molecular diagnostics, 18(1), 85-112.
37. Park, J. O., Nam, I. C., Kim, C. S., Park, S. J., Lee, D. H., Kim, H. B., ... & Joo, Y. H. (2022). Sex differences in the prevalence of head and neck cancers: A 10-Year follow-Up study of 10 million healthy people. Cancers, 14(10), 2521.
38. Arya, D., Sachithanandan, S. P., Ross, C., Palakodeti, D., Li, S., & Krishna, S. (2018). MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia. Cell death & disease, 8(1), e2547-e2547.
39. Li, N., Nan, C. C., Zhong, X. Y., Weng, J. Q., Fan, H. D., Sun, H. P., ... & Huang, S. X. (2018). miR-182-5p promotes growth in oral squamous cell carcinoma by inhibiting CAMK2N1. Cellular Physiology and Biochemistry, 49(4), 1329-1341.
40. Shao, N., Ma, G., Zhang, J., & Zhu, W. (2018). miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer. BMC urology, 18, 1-9.
41. Li, B., Lu, Y., Yu, L., Han, X., Wang, H., Mao, J., ... & Song, B. (2017). miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation. Chemico-biological interactions, 277, 33-42.
42. Liu, H., Chang, J. K., Hou, J. Q., Zhao, Z. H., & Zhang, L. D. (2017). Inhibition of miR-221 influences bladder cancer cell proliferation and apoptosis. Eur Rev Med Pharmacol Sci, 21(14), 3193-3199.
43. Li, B., Lu, Y., Wang, H., Han, X., Mao, J., Li, J., ... & Song, B. (2016). miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway. Biomedicine & Pharmacotherapy, 79, 93-101.
44. Pan, Y., Li, J., Zhang, Y., Wang, N., Liang, H., Liu, Y., ... & Gu, H. (2016). Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Scientific reports, 6(1), 1-14.
45. Zhou, L., Jiang, F., Chen, X., Liu, Z., Ouyang, Y., Zhao, W., & Yu, D. (2016). Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN. Oncology letters, 12(6), 4419-4426.
46. Du, L., Ma, S., Wen, X., Chai, J., & Zhou, D. (2017). Oral squamous cell carcinoma cells are resistant to doxorubicin through upregulation of miR 221. Molecular Medicine Reports, 16(3), 2659-2667.
47. Maxwell, P. (1999). Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker. British journal of biomedical science, 56(3), 209.
48. Kurokawa, H., Tsuru, S., Okada, M., Nakamura, T., & Kajiyama, M. (1993). Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity. International journal of oral and maxillofacial surgery, 22(1), 35-38.
49. Narimani, A., Hosseini, F., Bahrami, N., & Mohamadnia, A. (2019). The Expression of MicroRNA-155 (miR-155) and Carcinoembryonic Antigen Messenger RNA (CEA mRNA) in Peripheral Blood of Patients with Oral Squamous Cell Carcinomas (OSCC). Journal of Isfahan Medical School, 36(510), 1597-1601.
2. Petersen, P. E. (2003). The World Oral Health Report 2003: continuous improvement of oral health in the 21st century–the approach of the WHO Global Oral Health Programme. Community Dentistry and oral epidemiology, 31, 3-24.
3. Chester, D., Ephros, H., Haghighi, K., Kupiec-Sce, B., Lederman, D., Meddis, M., ... & Smith, S. L. (2008). Oral and Oropharyngeal Cancer. NJ, USA, Department of Health.
4. Woolgar, J. A. (2005). Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. oraloncology. 2005Oral Oncol. 2006 Mar; 42 (3): 229-39.
5. Aghiorghiesei, O., Zanoaga, O., Nutu, A., Braicu, C., Campian, R. S., Lucaciu, O., & Berindan Neagoe, I. (2022). The world of Oral cancer and its risk factors viewed from the aspect of MicroRNA expression patterns. Genes, 13(4), 594.
6. Rezapour, A., Jahangiri, R., Olyaeemanesh, A., Kalaghchi, B., Nouhi, M., & Nahvijou, A. (2018). The economic burden of oral cancer in Iran. PloS one, 13(9), e0203059.
7. Massano, J., Regateiro, F. S., Januário, G., & Ferreira, A. (2006). Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontology, 102(1), 67-76.
8. Cervino, G., Fiorillo, L., Herford, A. S., Romeo, U., Bianchi, A., Crimi, S., ... & Cicciù, M. (2019). Molecular biomarkers related to oral carcinoma: clinical trial outcome evaluation in a literature review. Disease markers, 2019.
9. Santosh, A. B. R., Jones, T., & Harvey, J. (2016). A review on oral cancer biomarkers: Understanding the past and learning from the present. Journal of cancer research and therapeutics, 12(2), 486-492.
10. Friedman, R. C., Farh, K. K. H., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome research, 19(1), 92-105.
11. Nagadia, R., Pandit, P., Coman, W. B., Cooper-White, J., & Punyadeera, C. (2013). miRNAs in head and neck cancer revisited. Cellular Oncology, 36, 1-7.
12. Troiano, G., Boldrup, L., Ardito, F., Gu, X., Muzio, L. L., & Nylander, K. (2016). Circulating miRNAs from blood, plasma or serum as promising clinical biomarkers in oral squamous cell carcinoma: A systematic review of current findings. Oral Oncology, 63, 30-37.
13. Arya, D., Sachithanandan, S. P., Ross, C., Palakodeti, D., Li, S., & Krishna, S. (2018). MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia. Cell death & disease, 8(1), e2547-e2547.
14. Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., ... & Garraway, L. A. (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer research, 68(3), 664-673.
15. Bandrés, E., Cubedo, E., Agirre, X., Malumbres, R., Zarate, R., Ramirez, N., ... & Garcia-Foncillas, J. (2006). Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Molecular cancer, 5(1), 1-10.
16. Agirre, X., Jiménez-Velasco, A., San José-Enériz, E., Garate, L., Bandrés, E., Cordeu, L., ... & Prosper, F. (2008). Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Molecular cancer research, 6(12), 1830-1840.
17. Navarro, A., Gaya, A., Martinez, A., Urbano-Ispizua, A., Pons, A., Balagué, O., ... & Monzo, M. (2008). MicroRNA expression profiling in classic Hodgkin lymphoma. Blood, The Journal of the American Society of Hematology, 111(5), 2825-2832.
18. Di Martino, M. T., Rossi, M., Caracciolo, D., Gullà, A., Tagliaferri, P., & Tassone, P. (2016). Mir-221/222 are promising targets for innovative anticancer therapy. Expert Opinion on Therapeutic Targets, 20(9), 1099-1108.
19. Xie, D., Yuan, P., Wang, D., Jin, H., & Chen, H. (2017). Expression and prognostic significance of miR-375 and miR-221 in liver cancer. Oncology Letters, 14(2), 2305-2309.
20. Hussein, S., Mosaad, H., Rashed, H. E., & El-Anwar, M. W. (2017). Up-regulated miR-221 expression as a molecular diagnostic marker in laryngeal squamous cell carcinoma and its correlation with Apaf-1 expression. Cancer Biomarkers, 19(3), 279-287.
21. Zhang, Y., Zhao, Y., Sun, S., Liu, Z., Zhang, Y., & Jiao, S. (2016). Overexpression of MicroRNA-221 is associated with poor prognosis in non-small cell lung cancer patients. Tumor Biology, 37, 10155-10160.
22. Wu, Q., Ren, X., Zhang, Y., Fu, X., Li, Y., Peng, Y., ... & Yin, G. (2018). MiR-221-3p targets ARF4 and inhibits the proliferation and migration of epithelial ovarian cancer cells. Biochemical and biophysical research communications, 497(4), 1162-1170.
23. Vergho, D. C., Kneitz, S., Kalogirou, C., Burger, M., Krebs, M., Rosenwald, A., ... & Kneitz, B. (2014). Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava. PloS one, 9(10), e109877.
24. Hall, C., Clarke, L., Pal, A., Buchwald, P., Eglinton, T., Wakeman, C., & Frizelle, F. (2019). A review of the role of carcinoembryonic antigen in clinical practice. Annals of coloproctology, 35(6), 294.
25. Grunnet, M., & Sorensen, J. B. (2012). Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung cancer, 76(2), 138-143.
26. Sørensen, C. G., Karlsson, W. K., Pommergaard, H. C., Burcharth, J., & Rosenberg, J. (2016). The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence–A systematic review. International Journal of Surgery, 25, 134-144.
27. Najafi, S., Khayamzadeh, M., Jafari Ghavamabad, A., Moradi, F., & Bafrouii, S. D. (2018). A 5 year Epidemiological Study on Oral and Pharyngeal Cancers from Cancer Registration Centers in Tehran. Journal of Iranian Medical Council, 1(2), 63-68.
28. Döbróssy, L. (2005). Epidemiology of head and neck cancer: magnitude of the problem. Cancer and Metastasis Reviews, 24, 9-17.
29. Silveira, A., Gonçalves, J., Sequeira, T., Ribeiro, C., Lopes, C., Monteiro, E., & Pimentel, F. L. (2012). Head and neck cancer: health related quality of life assessment considering clinical and epidemiological perspectives. Revista Brasileira de epidemiología, 15, 38-48.
30. Harding, S., Sanipour, F., & Moss, T. (2014). Existence of benefit finding and posttraumatic growth in people treated for head and neck cancer: a systematic review. PeerJ, 2, e256.
31. Yang, W., Zhao, S., Liu, F., & Sun, M. (2014). Health-related quality of life after mandibular resection for oral cancer: reconstruction with free fibula flap. Medicina oral, patologia oral y cirugia bucal, 19(4), e414.
32. Baykul, T., Yilmaz, H. H., Aydin, Ü., Aydin, M. A., Aksoy, M. C., & Yildirim, D. (2010). Early diagnosis of oral cancer. Journal of International Medical Research, 38(3), 737-749.
33. Scott, S. E., Grunfeld, E. A., & McGurk, M. (2006). Patient's delay in oral cancer: a systematic review. Community dentistry and oral epidemiology, 34(5), 337-343.
34. Dikova, V., Jantus-Lewintre, E., & Bagan, J. (2021). Potential non-invasive biomarkers for early diagnosis of oral squamous cell carcinoma. Journal of Clinical Medicine, 10(8), 1658.
35. Liang, K. H., Lin, Y. Y., Chiang, S. H., Tsai, E. T., Lo, W. L., Wang, C. L., ... & Hung, K. F. (2021). Recent progress of biomarkers in oral cancers. Journal of the Chinese Medical Association, 84(11), 987-992.
36. Arantes, L. M. R. B., De Carvalho, A. C., Melendez, M. E., & Lopes Carvalho, A. (2018). Serum, plasma and saliva biomarkers for head and neck cancer. Expert review of molecular diagnostics, 18(1), 85-112.
37. Park, J. O., Nam, I. C., Kim, C. S., Park, S. J., Lee, D. H., Kim, H. B., ... & Joo, Y. H. (2022). Sex differences in the prevalence of head and neck cancers: A 10-Year follow-Up study of 10 million healthy people. Cancers, 14(10), 2521.
38. Arya, D., Sachithanandan, S. P., Ross, C., Palakodeti, D., Li, S., & Krishna, S. (2018). MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia. Cell death & disease, 8(1), e2547-e2547.
39. Li, N., Nan, C. C., Zhong, X. Y., Weng, J. Q., Fan, H. D., Sun, H. P., ... & Huang, S. X. (2018). miR-182-5p promotes growth in oral squamous cell carcinoma by inhibiting CAMK2N1. Cellular Physiology and Biochemistry, 49(4), 1329-1341.
40. Shao, N., Ma, G., Zhang, J., & Zhu, W. (2018). miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer. BMC urology, 18, 1-9.
41. Li, B., Lu, Y., Yu, L., Han, X., Wang, H., Mao, J., ... & Song, B. (2017). miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation. Chemico-biological interactions, 277, 33-42.
42. Liu, H., Chang, J. K., Hou, J. Q., Zhao, Z. H., & Zhang, L. D. (2017). Inhibition of miR-221 influences bladder cancer cell proliferation and apoptosis. Eur Rev Med Pharmacol Sci, 21(14), 3193-3199.
43. Li, B., Lu, Y., Wang, H., Han, X., Mao, J., Li, J., ... & Song, B. (2016). miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway. Biomedicine & Pharmacotherapy, 79, 93-101.
44. Pan, Y., Li, J., Zhang, Y., Wang, N., Liang, H., Liu, Y., ... & Gu, H. (2016). Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Scientific reports, 6(1), 1-14.
45. Zhou, L., Jiang, F., Chen, X., Liu, Z., Ouyang, Y., Zhao, W., & Yu, D. (2016). Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN. Oncology letters, 12(6), 4419-4426.
46. Du, L., Ma, S., Wen, X., Chai, J., & Zhou, D. (2017). Oral squamous cell carcinoma cells are resistant to doxorubicin through upregulation of miR 221. Molecular Medicine Reports, 16(3), 2659-2667.
47. Maxwell, P. (1999). Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker. British journal of biomedical science, 56(3), 209.
48. Kurokawa, H., Tsuru, S., Okada, M., Nakamura, T., & Kajiyama, M. (1993). Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity. International journal of oral and maxillofacial surgery, 22(1), 35-38.
49. Narimani, A., Hosseini, F., Bahrami, N., & Mohamadnia, A. (2019). The Expression of MicroRNA-155 (miR-155) and Carcinoembryonic Antigen Messenger RNA (CEA mRNA) in Peripheral Blood of Patients with Oral Squamous Cell Carcinomas (OSCC). Journal of Isfahan Medical School, 36(510), 1597-1601.
| Files | ||
| Issue | Vol 10, No 1 (Winter 2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jcr.v10i1.13677 | |
| Keywords | ||
| OSCC; MiR-182; MiR-221; CEA; Biomarker. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Rasouli A, Arzi L, Khademi S, Mohamadnia A. Assessment of miR-182, miR-221 and CEA expression in the peripheral blood of oral squamous cell carcinoma (OSCC) patients. J Craniomaxillofac Res. 2023;10(1):18-26.
